{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:44Z","timestamp":1761870644454,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.clml.2014.07.013","type":"journal-article","created":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T20:01:34Z","timestamp":1406923294000},"page":"e43-e46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ofatumumab in Refractory Chronic Lymphocytic Leukemia: Experience Through the French Early Access Program"],"prefix":"10.1016","volume":"15","author":[{"given":"J.","family":"Dupuis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Brice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"de Guibert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lepr\u00eatre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.","family":"Dilhuydy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Fornecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tempescul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.07.013_bib1","unstructured":"Monnereau A. National estimate of the incidence of cancer in France between 1980 and 2012: a study based on Francim network of cancer registries, part 2\u2014hematological malignancies. Available at: http:\/\/www.invs.sante.fr\/Publications-et-outils\/Rapports-et-syntheses\/Maladies-chroniques-et-traumatismes\/2013\/Estimation-nationale-de-l-incidence-des-cancers-en-France-entre-1980-et-2012. Accessed: March\u00a018, 2014."},{"key":"10.1016\/j.clml.2014.07.013_bib2","unstructured":"Projection de l\u2019incidence et de la mortalit\u00e9 par cancer en France en 2010. Available at: http:\/\/www.invs.sante.fr\/applications\/cancers\/projections2010\/rapport_projections_nationales_cancer_2010.pdf. Accessed: March 19,\u00a02014."},{"key":"10.1016\/j.clml.2014.07.013_bib3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.0900632","article-title":"Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX","volume":"183","author":"Pawluczkowycz","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2014.07.013_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4049\/jimmunol.1202645","article-title":"Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy","volume":"190","author":"Bologna","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2014.07.013_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMp1208347","article-title":"France's new framework for regulating off-label drug use","volume":"367","author":"Emmerich","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.07.013_bib6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1634\/theoncologist.2010-0255","volume":"15","author":"Gravanis","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2014.07.013_bib7","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.013_bib8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.013_bib9","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.013_bib10","unstructured":"Arzerra: summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001131\/WC500093091.pdf."},{"key":"10.1016\/j.clml.2014.07.013_bib11","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.013_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/ejh.12065","article-title":"A\u00a0case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p","volume":"90","author":"Namberger","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.07.013_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2141.2011.08711.x","article-title":"Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme","volume":"155","author":"Chowdhury","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014003085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014003085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:55Z","timestamp":1761870355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014003085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S2152265014003085"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.07.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ofatumumab in Refractory Chronic Lymphocytic Leukemia: Experience Through the French Early Access Program","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}